PerkinElmer launched an assay development service for assays in advanced cellular science and drug discovery research. The new service offers assay solutions for GPCR and kinase cell-based screening, including high-throughput platforms such as the AlphaScreen®, AequoScreen®, Delfia®, and Lance® technologies.
Optimized reporter gene assays are available utilizing steadylite plus™ and britelite plus™ technologies. The service also offers biochemical enzyme and radio ligand binding assays on the FlashPlate® or Image FlashPlate® platforms in 384-well or 96-well formats.
The assay development service will also provide miniaturization of immunoassays. PerkinElmer’s AlphaLISA™ technology offers a homogenous alternative to traditional ELISAs, enabling labs to easily automate these assays for greater productivity and throughput while achieving higher sensitivity, a wider dynamic range, and therefore, more relevant data, according to the company. The service will facilitate a seamless conversion from ELISA to this new enabling technology.
Following scientific consultation with the laboratory, PerkinElmer will propose development and validation studies and cost estimates. The studies may include anything from initial assay formatting and feasibility, to optimization of the assay protocol for robustness, to validation of performance characteristics such as reproducibility. PerkinElmer assay development typically takes two to four weeks. Subsequent training, assay transfer, and validation at the customer site are supported by PerkinElmer’s scientists.